Roche Diagnostics, Redcliffe Labs collaborate for early Alzheimer's prediction

Through the collaboration, Redcliffe Labs will be the first to bring to India Roche Diagnostics' Elecsys ß-Amyloid (1-42) CSF II (cerebrospinal fluid), Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF immunoassays. Elecsys AD CSF tests are intended for use in adult patients with cognitive impairment to aid in the early diagnosis of Alzheimer's disease (AD) and to identify patients with mild cognitive impairment (MCI) who are at increased risk of cognitive decline.

Elecsys AD CSF assays can detect amyloid positivity, enhancing diagnostic accuracy and physician confidence. These in-vitro diagnostic immunoassays are for the measurement of ß-Amyloid (1–42), phospho-Tau, and total Tau protein concentrations in CSF of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of dementia.

Mr. Dheeraj Jain, the Founder & Managing Director of Redcliffe Labs said "Alzheimer's has a significant adverse impact on public health, including incidence, mortality, morbidity, and associated costs of care. More than 5 million people in India alone suffer from dementia, with AD thought to account for 60% to 80% of cases. Currently, a considerable portion of AD diagnoses are made mainly on clinical symptoms, including cognitive tests, and many people are identified after their illness is extremely advanced. 50% to 75% of those who have dementia do not have an official MCI or AD diagnosis. Furthermore, 70 to 80 percent of AD diagnoses are correct when based solely on cognitive tests. This partnership between Redcliffe Labs and Roche Diagnostics will mark a significant turning point as, with the help of CSF immunoassays, the accuracy of an AD diagnosis is increased and the development of the disease can be assessed by doctors."